Get started
Author

Mary A. Cifaldi

Societal cost of rheumatoid arthritis patients in the US
2009 · Howard Birnbaum, Crystal Pike, et al. · Current Medical Research and Opinion · 248
Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: A population‐based study
2011 · Shelagh M. Szabo, Adrian R. Levy, et al. · Arthritis & Rheumatism · 222
Prevalence of Axial Spondyloarthritis in United States Rheumatology Practices: Assessment of SpondyloArthritis International Society Criteria Versus Rheumatology Expert Clinical Diagnosis
2013 · Vibeke Strand, Sumati A. Rao, et al. · Arthritis Care & Research · 130
Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study
2011 · VIBEKE STRAND, ANNE M. RENTZ, et al. · The Journal of Rheumatology · 86
PDF
Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA.
2008 · Miriam Kimel, Mary Cifaldi, et al. · PubMed · 71
Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
2012 · Josef S Smolen, Désirée M van der Heijde, et al. · Annals of the Rheumatic Diseases · 70
PDF
Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: Work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study
2010 · Ronald F. van Vollenhoven, Mary A. Cifaldi, et al. · Arthritis Care & Research · 64
Cost Per Responder Associated with Biologic Therapies for Crohn’s Disease, Psoriasis, and Rheumatoid Arthritis
2012 · Yifei Liu, Eric Q. Wu, et al. · Advances in Therapy · 61
PDF
Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents
2012 · Xin Gao, Daniel Wendling, et al. · Journal of Medical Economics · 52
PDF
Estimating the Occurrence of Renal Complications Among Persons With Ankylosing Spondylitis
2013 · Adrian R. Levy, Shelagh M. Szabo, et al. · Arthritis Care & Research · 50
Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis
2008 · Eric Wu, Lei Chen, et al. · Current Medical Research and Opinion · 49
Worker Productivity Outcome Measures: OMERACT Filter Evidence and Agenda for Future Research
2013 · Kenneth Tang, Annelies Boonen, et al. · The Journal of Rheumatology · 46
PDF
Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid Arthritis
2008 · ANDREW DAVIES, MARY A. CIFALDI, et al. · The Journal of Rheumatology · 46
PDF
Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting
2017 · Jordana Schmier, Kristine Ogden, et al. · Clinical Therapeutics · 43
Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults
2006 · Philip A. Giordano, Dirk Elston, et al. · Current Medical Research and Opinion · 40
Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data
2007 · Eric Wu, Lei Chen, et al. · Current Medical Research and Opinion · 37
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
2014 · Sarah Neubauer, Mary Cifaldi, et al. · Health Economics Review · 35
PDF
Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis.
2007 · Thomas Mittendorf, Birgitta Dietz, et al. · PubMed · 34
Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis
2015 · Onur Baser, Arijit Ganguli, et al. · Clinical Therapeutics · 28
PDF
Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis
2013 · Noam Y. Kirson, Sumati Rao, et al. · Journal of Medical Economics · 27
PDF
Disparities in care by insurance status for individuals with rheumatoid arthritis: analysis of the medical expenditure panel survey, 2006–2009
2016 · Mary Cifaldi, Jeanette Renaud, et al. · Current Medical Research and Opinion · 26
Annual Incremental Health Benefit Costs and Absenteeism Among Employees With and Without Rheumatoid Arthritis
2013 · Nathan L. Kleinman, Mary A. Cifaldi, et al. · Journal of Occupational and Environmental Medicine · 26
Changes in Utilization and Costs for Patients with Rheumatoid Arthritis, 1997 to 2006
2012 · Howard G. Birnbaum, Crystal Pike, et al. · PharmacoEconomics · 23
Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid Arthritis
2011 · Spyros Stavrakas, Bruce Wong, et al. · Journal of Managed Care Pharmacy · 19
PDF
A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: A multicenter, prospective, single-blind study
2005 · Stan L. Block, Mary Cifaldi, et al. · Clinical Therapeutics · 17
Works count: 44
Citation count: 1,617
H-index: 23
I10-index: 29
Year
Topic
Type